Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.
Gavin C Donaldson, Martin Law, Beverly Kowlessar...
https://pubmed.ncbi.nlm.nih.gov/26151174/Actively Recruiting
Led by National University of Malaysia · Updated on 2025-11-19
100
Participants Needed
2
Research Sites
N/A
Total Duration
Chronic Obstructive Pulmonary Disease COPD is a leading cause of death worldwide affecting over 300 million people, often leading to frequent exacerbations that worsen health and quality of life. This research evaluates the efficacy and safety of two mucolytic treatments, dry powder Ivy Extract Syrup Prospan and N-Acetylcysteine NAC, in managing COPD symptoms and preventing exacerbations. The study aims to compare cough symptoms, quality of life, lung function, and patient satisfaction between these treatments over 30 days. Participants with stable COPD will be randomly assigned to receive either Syrup Prospan 7.5 mL twice daily or N-Acetylcysteine 600 mg twice daily for one month. The study is open-label and will run from May 2024 to November 2026. Both groups will be monitored for adherence, side effects, and treatment satisfaction. The trial aims to recruit around 100 participants, equally divided between the two treatments. Participants will undergo baseline evaluations including spirometry, COPD assessment tests, and questionnaires on cough and quality of life before starting treatment. Follow-up visits will occur on Day 15 and Day 30 to assess compliance and repeat tests. Researchers will measure cough severity using the Cough and Sputum Assessment Questionnaire, quality of life with the McGill COPD Questionnaire, and lung function by spirometry. Safety and treatment satisfaction will also be monitored throughout the 30-day period.
CONDITIONS
Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients
M
Mohamed Faisal Abdul Hamid, MBBS (IIUM)
M
Mohamed FaisalM Abdul Hamid, MBBS (IIUM)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National University of Malaysia
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 30 days
Participants receive either Syrup Prospan or N-Acetylcysteine for 1 month to assess efficacy and safety for COPD symptoms.
3 visits (Day 0, Day 15, and Day 30 assessments in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gavin C Donaldson, Martin Law, Beverly Kowlessar...
https://pubmed.ncbi.nlm.nih.gov/26151174/J Garrard, S J Rolnick, N M Nitz...
https://pubmed.ncbi.nlm.nih.gov/9520914/Phillippa Poole, Kavin Sathananthan, Rebecca Fortescue
https://pubmed.ncbi.nlm.nih.gov/31107966/R Balsamo, L Lanata, C G Egan
https://pubmed.ncbi.nlm.nih.gov/20956181/Terence A R Seemungal, John R Hurst, Jadwiga A Wedzicha
https://pubmed.ncbi.nlm.nih.gov/19554195/GBD 2017 DALYs and HALE Collaborators
https://pubmed.ncbi.nlm.nih.gov/30415748/G C Donaldson, J A Wedzicha
https://pubmed.ncbi.nlm.nih.gov/16443707/Yong Du, Ingrid-Katharina Wolf, Wanli Zhuang...
https://pubmed.ncbi.nlm.nih.gov/24988878/National University of Malaysia
Lead Sponsor